+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SYNCOMF

Syncom Formulation (India) Share Price

₹13.45 +0.27 (2.05%)
28.46% Fall from 52W High

07 Aug, 2026 3:55 PM (IST)

Syncom Formulation (India) live price: ₹13.45. It opened at ₹13 vs previous close ₹13; intraday high/low: ₹14/₹13. The 50 & 200 DMA stand at ₹13.60/₹14.30.

Syncom Formulation (India) Performance

  • Today's Low
  • ₹13
  • Today's High
  • ₹14
  • 52 Week Low
  • ₹10
  • 52 Week High
  • ₹19
  • Open Price₹13
  • Previous Close₹13
  • Volume2,109,928
  • 50 DMA₹13.60
  • 100 DMA₹13.80
  • 200 DMA₹14.30

Syncom Formulation (India) Chart

Investment Returns

  • Over 1 Month -1.25%
  • Over 3 Month -8.32%
  • Over 6 Month -1.47%
  • Over 1 Year -26.38%

Smart Investing Starts Here Start SIP with Syncom Formulation (India) for Steady Growth!

Invest Now

Syncom Formulation (India) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 16.5
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 1,264
  • P/B Ratio
  • 3
  • Average True Range
  • 0.4
  • EPS
  • 0.8
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.2
  • RSI
  • 49.22
  • MFI
  • 38.18

Latest Stock News Updates

Syncom Formulations India Ltd-$ - 524470 - Announcement under Regulation 30 (LODR)-Resignation of Managing Director

Intimation for Resignation of Mr. Vijay Shankarlal Bankda Managing Director under Regulation 30 of SEBI (LODR) Regulations, 2015

Syncom Formulations India Ltd-$ - 524470 - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)

Intimation for Resignation of Mr. Rahul Vijay Bankda Chief Financial Officer (CFO) under Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015

Syncom Formulations India Ltd-$ - 524470 - Announcement under Regulation 30 (LODR)-Resignation of Director

Intimation for Resignation of Mr. Kedarmal Shankarlal Bankda Whole-Time Director under Regulation 30 of SEBI (Listing Obligation & Disclosure Requirement) Regulation, 2015

Syncom Formulation (India) Financials

Syncom Formulation (India) Technicals

EMA & SMA

Current Price
₹13.45
+ 0.27 (2.05%)
pointer
  • Bearish Moving Average 8
  • Bullish Moving Average 8
  • 20 Day
  • ₹13.40
  • 50 Day
  • ₹13.60
  • 100 Day
  • ₹13.80
  • 200 Day
  • ₹14.30

Resistance and Support

13.35 Pivot Speed
  • R3 14.00
  • R2 13.70
  • R1 13.60
  • S1 13.20
  • S2 13.00
  • S3 12.80

Syncom Formulation (India) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-11 Quarterly Results, Final Dividend & A.G.M.
2026-05-22 Audited Results
2026-02-12 Quarterly Results
2025-11-12 Quarterly Results
2025-08-08 Quarterly Results & A.G.M.
Date Purpose Remarks
2013-08-20 Split

Syncom Formulation (India) Shareholding Pattern

50.57%
49.07%
0.35%
0%

About Syncom Formulation (India)

Syncom Formulations (India) is a renowned name in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Currently Syncom manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. View More
  • NSE Symbol
  • SYNCOMF
  • BSE Symbol
  • 524470
  • ISIN
  • INE312C01025

Similar Stocks to Syncom Formulation (India)

Syncom Formulation (India) FAQs

Syncom Formulation (India) share price is ₹13 As on 09 August, 2026 | 07:33

The Market Cap of Syncom Formulation (India) is ₹1264.3 Cr As on 09 August, 2026 | 07:33

The P/E ratio of Syncom Formulation (India) is 16.5 As on 09 August, 2026 | 07:33

The PB ratio of Syncom Formulation (India) is 3 As on 09 August, 2026 | 07:33

The 52 week High & Low of Syncom Formulation (India) is ₹18.8/₹10.2 respectively As on 09 August, 2026 | 07:33

Open FREE Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23